Harpoon Therapeutics
2015
FOUNDED
PUBLIC
STATUS
51-60
EMPLOYEES
HARP
STOCK SYMBOL
$13.81
SHARE PRICE
(As of Wednesday Closing)
Description
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 4000 Shoreline Court
- Suite 250
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Harpoon Therapeutics’s full profile, request a free trial.
Harpoon Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $9.07 - $21.47 | $340M | $14.14 | -$2.98 | 113K | 24.6M |
Harpoon Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 216,898 | |||
| Revenue | 4,604 | 4,750 | 708 | 0 |
| EBITDA | (52,729) | (27,117) | (16,257) | (10,953) |
| Net Income | (51,036) | (27,366) | (16,830) | (11,406) |
| Total Assets | 142,388 | 102,580 | 31,872 | 8,384 |
| Total Debt | 15,038 | 0 | 0 | 2,312 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Harpoon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Harpoon Therapeutics‘s full profile, request access.
Request full access to PitchBookHarpoon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Harpoon Therapeutics‘s full profile, request access.
Request full access to PitchBookHarpoon Therapeutics Competitors (37)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Jounce Therapeutics | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 00000000000 | Formerly VC-backed | Hayward, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 00000000 | 00000 |
Harpoon Therapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Harpoon Therapeutics‘s full profile, request access.
Request full access to PitchBookHarpoon Therapeutics Executive Team (7)
2 Former Executives
You’re viewing 5 of 7 executives. Get the full list »Harpoon Therapeutics Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Gerald McMahon Ph.D | Harpoon Therapeutics | Chief Executive Officer & Board Member | 000 0000 | |
| Jonathan Drachman MD | Self | Board Member | 000 0000 | |
| Julie Eastland | Self | Board Member | 000 0000 | |
| Luke Evnin Ph.D | Self | Chairman & Founder | 000 0000 | |
| Mark Chin | Arix Bioscience | Board Member | 000 0000 |